Having more refined mouse models of metabolic dysfunction-associated steatotic liver disease (MASLD; also known as nonalcoholic fatty liver disease) will help to advance research into this disease. In their study, Jeong and colleagues use streptozotocin together with a high-fat diet for 6–60 weeks to investigate the progression from MASLD to hepatocellular carcinoma.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jeong, B. K. & Choi, W. I. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nat. Commun. 15, 6506 (2024).
Fujii, M. & Shibazaki, Y. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46, 141–152 (2013).
Lo, L. & McLennan, S. V. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J. Hepatol. 55, 435–444 (2011).
Abbasi, J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. J. Am. Med. Assoc 330, 2143–2144 (2023).
Tsuchida, T. & Lee, Y. A. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 69, 385–395 (2018).
Gallage, S. & Avila, J. E. B. A researcher’s guide to preclinical mouse NASH models. Nat. Metab 4, 1632–1649 (2022).
Vacca, M. & Kamzolas, I. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nat. Metab 6, 1178–1196 (2024).
FDA approves first MASH drug. Nat. Biotechnol. 42, 540 (2024).
Harrison, S. A. & Bedossa, P. A. Phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024).
Kim, H. Y. & Lee, W. Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress. STAR Protoc. 5, 103111 (2024).
Acknowledgements
The authors acknowledge the support of a German Research Foundation grant (DFG-Grant 1402/1) awarded to C.S.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.E.F. is an employee and stockholder of Novo Nordisk. C.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Stoess, C., Feldstein, A.E. Modelling human liver disease: from steatotic liver disease to MASH-HCC. Nat Rev Endocrinol 21, 10–11 (2025). https://doi.org/10.1038/s41574-024-01054-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41574-024-01054-z
